elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q58714451
Q58714451
Item
http://www.wikidata.org/entity/Q58714451
Q58714451
about
Q58714451
Item
http://www.wikidata.org/entity/Q58714451
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
type
Item
P1433
Q58714451-308AF7A9-62BF-44FB-AE9C-E7996C905DF1
P2093
Q58714451-5F72735E-78BD-4AD2-B418-D06326922619
Q58714451-8A14131D-31AE-4AB7-B252-16712E426B41
P2860
Q58714451-06196757-4D12-47A1-BE63-212A6B5062B4
Q58714451-0AE00AFD-0436-43FA-B65B-E86425DF4597
Q58714451-2C8F5C7A-0A85-4B0B-ABAE-4F0D83C93D88
Q58714451-340DA1B7-8F08-4116-8A20-90AD717574C5
Q58714451-54F6DA03-1E33-4E08-8F00-7545B8602F7A
Q58714451-58FBA7FA-E396-4374-A5D8-03E9C8E72679
Q58714451-5A10D583-21D0-4924-992B-44D01C03245C
Q58714451-672F26C0-9F20-4ED0-B817-78900FF996C5
Q58714451-6735B171-24DB-4027-BBB1-848576B9B50A
Q58714451-68E0D01D-3586-4972-ABB4-EADA30CF2A6B
Show more
P304
Q58714451-5919AEDC-8639-45BB-A14A-F23191C43753
P31
Q58714451-70ec49ef-41ef-46c4-99dc-c60ec6247c29
Q58714451-D8CBEE1F-C96D-424A-9608-42EF71547CD0
P356
Q58714451-4FEACAFF-4F80-4BE5-B4FD-33710A948D6A
P433
Q58714451-1D82D271-934E-4F86-85FF-E2094984BF5D
P478
Q58714451-88C2E48F-069D-4719-BA8E-740F6CE8FACE
P577
Q58714451-AEEDB18E-3705-4466-B3E6-23E70F77B505
P698
Q58714451-23B71BBA-6D15-4BCD-B109-540E2DECD03C
P932
Q58714451-FF0EEC15-D586-423D-A114-AB48208EF7F1
P356
J.ISSN.1009-3419.2018.09.07
P1433
Zhongguo fei ai za zhi
P2093
Diansheng Zhong
http://www.w3.org/2001/XMLSchema#string
Xin Wang
http://www.w3.org/2001/XMLSchema#string
P2860
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation
Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study
Show more
P304
686-691
http://www.w3.org/2001/XMLSchema#string
P31
scholarly article
meta-analysis
P356
10.3779/J.ISSN.1009-3419.2018.09.07
http://www.w3.org/2001/XMLSchema#string
P433
9
http://www.w3.org/2001/XMLSchema#string
P478
21
http://www.w3.org/2001/XMLSchema#string
P577
2018-09-20T00:00:00Z
http://www.w3.org/2001/XMLSchema#dateTime
P698
30201068
http://www.w3.org/2001/XMLSchema#string
P932
6136996
http://www.w3.org/2001/XMLSchema#string